These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 27557847)
1. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. Ceci F; Castellucci P; Nanni C; Fanti S Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2103-2104. PubMed ID: 27557847 [No Abstract] [Full Text] [Related]
2. Prospective evaluation of [ Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. Ceci F; Castellucci P; Mapelli P; Incerti E; Picchio M; Fanti S J Nucl Med; 2016 Oct; 57(Suppl 3):49S-54S. PubMed ID: 27694172 [TBL] [Abstract][Full Text] [Related]
4. Imaging of Prostate Cancer Using Castellucci P; Ceci F; Fanti S PET Clin; 2017 Apr; 12(2):137-143. PubMed ID: 28267448 [TBL] [Abstract][Full Text] [Related]
5. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138 [TBL] [Abstract][Full Text] [Related]
6. 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. Mapelli P; Incerti E; Ceci F; Castellucci P; Fanti S; Picchio M J Nucl Med; 2016 Oct; 57(Suppl 3):43S-48S. PubMed ID: 27694171 [TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer. Kelly R; Jensen A; Karunaratna N; Wong S; Shapiro J; Weickhardt A; Parente P; Azad AA; Uccellini A; Torres J; Parnis F; Goh J; Kwan EM; Brown S; Steer C; Warren M; Gibbs P; Tran B; Anton A BJU Int; 2023 Feb; 131(2):179-182. PubMed ID: 36371671 [No Abstract] [Full Text] [Related]
8. [Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer]. Kretschmer A; Tilki D Urologe A; 2019 May; 58(5):529-534. PubMed ID: 30887058 [TBL] [Abstract][Full Text] [Related]
9. A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab. Basnet A; Khullar G; Mehta R; Chittoria N Clin Genitourin Cancer; 2017 Oct; 15(5):e881-e884. PubMed ID: 28625691 [No Abstract] [Full Text] [Related]
10. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Shamchi SP; Werner TJ; Aydin A; Roy SG; Alavi A; Kumar R Hell J Nucl Med; 2016; 19(3):254-268. PubMed ID: 27824966 [TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer CRPC Stage M0 and M1: Do We Need Stage M0.5? Gomella LG Can J Urol; 2018 Apr; 25(2):9220. PubMed ID: 29679997 [No Abstract] [Full Text] [Related]
12. Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. Morin F; Beauregard JM; Bergeron M; Nguile Makao M; Lacombe L; Fradet V; Fradet Y; Pouliot F Eur Urol Focus; 2017 Dec; 3(6):639-642. PubMed ID: 28753860 [TBL] [Abstract][Full Text] [Related]
13. Response to 'Commentary to "Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image."'. Minamimoto R Nucl Med Commun; 2016 Aug; 37(8):888. PubMed ID: 27348243 [No Abstract] [Full Text] [Related]
14. Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al. Onal C; Oymak E; Guler OC Med Oncol; 2021 Jun; 38(7):81. PubMed ID: 34115258 [No Abstract] [Full Text] [Related]
15. [Imaging diagnostics in bone metastases]. Kintzelé L; Weber MA Radiologe; 2017 Feb; 57(2):113-128. PubMed ID: 28130579 [TBL] [Abstract][Full Text] [Related]
16. Commentary to 'Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image'. Havariyoun G Nucl Med Commun; 2016 Aug; 37(8):888. PubMed ID: 27348242 [No Abstract] [Full Text] [Related]
17. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. Spick C; Herrmann K; Czernin J J Nucl Med; 2016 Oct; 57(Suppl 3):30S-37S. PubMed ID: 27694168 [TBL] [Abstract][Full Text] [Related]
18. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]. Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S Urologe A; 2016 Sep; 55(9):1206-12. PubMed ID: 27411995 [TBL] [Abstract][Full Text] [Related]
19. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. Woff E; Hendlisz A; Garcia C; Deleporte A; Delaunoit T; Maréchal R; Holbrechts S; Van den Eynde M; Demolin G; Vierasu I; Lhommel R; Gauthier N; Guiot T; Ameye L; Flamen P Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1792-801. PubMed ID: 27072811 [TBL] [Abstract][Full Text] [Related]
20. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer? Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439 [No Abstract] [Full Text] [Related] [Next] [New Search]